These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1174 related articles for article (PubMed ID: 30390221)

  • 21. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
    Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
    Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis.
    Tong J; Ji T; Liu T; Liu J; Chen Y; Li Z; Lu N; Li Q
    Epilepsy Behav; 2024 Mar; 152():109653. PubMed ID: 38277848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.
    Lattanzi S; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M; Brigo F
    CNS Drugs; 2020 Nov; 34(11):1105-1120. PubMed ID: 32851590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
    Privitera M; Bhathal H; Wong M; Cross JH; Wirrell E; Marsh ED; Mazurkiewicz-Beldzinska M; Villanueva V; Checketts D; Knappertz V; VanLandingham K
    Epilepsia; 2021 May; 62(5):1130-1140. PubMed ID: 33797076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
    N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
    Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
    JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
    Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C
    Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials.
    Madan Cohen J; Checketts D; Dunayevich E; Gunning B; Hyslop A; Madhavan D; Villanueva V; Zolnowska M; Zuberi SM
    Epilepsia; 2021 Sep; 62(9):2218-2227. PubMed ID: 34265088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
    García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
    Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial.
    Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O
    Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
    Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C
    Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
    Koo CM; Kim SH; Lee JS; Park BJ; Lee HK; Kim HD; Kang HC
    J Korean Med Sci; 2020 Dec; 35(50):e427. PubMed ID: 33372424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
    Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
    N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
    Reddy DS
    Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.